0 14 Nonradioactive nonradioactive JJ 15 29 quantification quantification NN 30 32 of of IN 33 47 glucocorticoid glucocorticoid NN 48 56 receptor receptor NN 57 67 expression expression NN 68 74 during during IN 75 90 differentiation differentiation NN 91 93 of of IN 94 99 human human JJ 100 109 monocytic monocytic JJ 110 115 cells cell NNS 116 117 ( ( ( 117 121 U937 u937 NN 121 122 ) ) ) 122 123 . . . 125 127 We we PRP 128 136 describe describe VBP 137 138 a a DT 139 145 method method NN 146 149 for for IN 150 158 relative relative JJ 159 173 quantification quantification NN 174 176 of of IN 177 185 specific specific JJ 186 190 mRNA mrna NN 191 196 using use VBG 197 198 a a DT 199 213 nonradioactive nonradioactive JJ 214 219 assay assay NN 220 225 based base VBN 226 228 on on IN 229 232 DNA DNA NNP 233 239 strand strand NN 240 251 competition competition NN 252 259 between between IN 260 269 identical identical JJ 270 279 sequences sequence NNS 280 282 of of IN 283 290 biotin- biotin- NN 291 294 and and CC 295 314 fluorescein-labeled fluorescein-labeled JJ 315 323 amplicon amplicon NN 324 325 ( ( ( 325 330 probe probe NN 330 331 ) ) ) 332 335 and and CC 336 345 unlabeled unlabeled JJ 346 354 amplicon amplicon NN 355 356 ( ( ( 356 362 target target NN 362 363 ) ) ) 364 370 during during IN 371 384 hybridization hybridization NN 384 385 . . . 386 388 As as IN 389 392 the the DT 393 399 target target NN 400 408 quantity quantity NN 409 418 increased increase VBD 418 419 , , , 420 424 that that DT 425 427 of of IN 428 431 the the DT 432 446 double-labeled double-labeled JJ 447 452 probe probe NN 453 462 decreased decrease VBD 463 465 in in IN 466 476 accordance accordance NN 477 481 with with IN 482 485 the the DT 486 490 mass mass NN 491 497 action action NN 498 501 law law NN 501 502 . . . 503 507 This this DT 508 517 technique technique NN 518 521 was be VBD 522 534 successfully successfully RB 535 542 applied apply VBN 543 545 to to TO 546 554 evaluate evaluate VB 555 566 differences difference NNS 567 569 in in IN 570 584 glucocorticoid glucocorticoid NN 585 593 receptor receptor NN 594 604 expression expression NN 605 607 in in IN 608 612 U937 u937 NN 613 618 cells cell NNS 619 625 before before IN 626 629 and and CC 630 635 after after IN 636 639 the the DT 640 648 addition addition NN 649 651 of of IN 652 658 potent potent JJ 659 674 differentiation differentiation NN 675 683 inducers inducer NNS 683 684 : : : 685 710 12-O-tetradecanoylphorbol 12-O-tetradecanoylphorbol NNP 711 721 13-acetate 13-acetate NN 722 723 ( ( ( 723 726 TPA TPA NNP 726 727 ) ) ) 728 731 and and CC 732 733 a a DT 734 745 combination combination NN 746 748 of of IN 749 758 all-trans all-trans JJ 759 767 retinoic retinoic JJ 768 772 acid acid NN 773 774 ( ( ( 774 776 RA RA NNP 776 777 ) ) ) 778 781 and and CC 782 803 1,25-dihydroxyvitamin 1,25-dihydroxyvitamin NN 804 806 D2 d2 NN 807 808 ( ( ( 808 810 VD VD NNP 810 811 ) ) ) 811 812 . . . 813 815 We we PRP 816 824 observed observe VBD 825 829 that that IN 830 833 TPA TPA NNP 834 843 treatment treatment NN 844 847 was be VBD 848 858 associated associate VBN 859 863 with with IN 864 866 an an DT 867 875 increase increase NN 876 878 in in IN 879 887 specific specific JJ 888 895 binding binding NN 896 898 of of IN 899 900 [ [ ( 900 916 3H]dexamethasone 3H]dexamethasone NNP 917 920 and and CC 921 934 up-regulation up-regulation NN 935 937 of of IN 938 940 GR GR NNP 941 945 mRNA mRNA NNP 946 951 while while IN 952 954 no no DT 955 963 enhanced enhance VBN 964 966 GR gr NN 967 977 expression expression NN 978 981 was be VBD 982 991 perceived perceive VBN 992 996 with with IN 997 1002 RA/VD RA/VD NNP 1003 1012 treatment treatment NN 1012 1013 . . .